Perspectives in beta 2-agonist therapy: vox clamantis in deserto vel lux in tenebris?

J Allergy Clin Immunol. 1995 Mar;95(3):641-51. doi: 10.1016/s0091-6749(95)70166-4.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Adrenergic beta-Agonists / administration & dosage
  • Adrenergic beta-Agonists / adverse effects
  • Adrenergic beta-Agonists / therapeutic use*
  • Aerosols
  • Asthma / drug therapy*
  • Asthma / mortality
  • Clinical Trials as Topic
  • Forecasting
  • Humans
  • Risk Factors

Substances

  • Adrenergic beta-Agonists
  • Aerosols